Sanofi Revamps Commercial Ops, Prioritizes Fixed-Ratio Lantus-Lyxumia Combo
This article was originally published in The Pink Sheet Daily
Sanofi plans to split its commercial organization into two units as the French drug giant starts to emerge from its patent cliff with a return to growth and a renewed focus on new diabetes therapies.
You may also be interested in...
Novo Struggles In Japan, Sanofi Struggles With Distributors: Emerging Markets Earnings Roundup (Part 7)
Both Novo Nordisk and Sanofi had a bumpy start of the year in Asia and emerging markets. Novo saw insulin sales decline in Japan and Korea, while Sanofi grew only 6.5% in emerging markets, well below the company’s long-term guidance of double-digit growth.
With the removal of a near-term competitive threat to Sanofi’s hallmark insulin franchise, 2013 is poised to be a momentum-building year for the big pharma, and more specifically, its diabetes business. The opportunity can’t come too soon, as the company launches the GLP-1 agonist Lyxumia into a crowded and fiercely competitive field.
Inovio Pharmaceuticals has reported promising initial data from its first Phase III study of its electrical current-driven DNA plasmid-based immunotherapy, VGX-3100, in virus-associated cervical dysplasia; it is heading a small group of companies evaluating novel therapies in the condition, which often advances to cancer.